Welcome to the ePoster Viewing Panel of AICOG 2025

Introduction: Development of pathology in one or both conserved ovaries in patients who underwent salpingo-ophorectomy with/without hysterectomy is called Residual Ovarian Syndrome (ROS). It presents with chronic pelvic pain, pelvic mass, dyspareunia etc. We report a case of 55 year old patient with Malignant Brenners tumour (MBT) arising from Residual Ovary; revealed by a hemorrhagic pelvic mass, 10 years after total hysterectomy with bilateral adnexectomy for uterine fibroma , with classic symptoms and imaging and pathology findings, and review the treatment. Aims and Objectives: To report and analyze the clinical presentation, diagnostic challenges, and management of a rare case of Malignant Brenner's Tumor (MBT) associated with Residual Ovarian Syndrome (ROS), highlighting its pathological features, treatment approach, and outcomes. Material and Methods: This case report highlights a rare instance of Malignant Brenner's Tumor (MBT) with Residual Ovarian Syndrome (ROS). Clinical history, imaging (ultrasound, MRI), and tumor markers (e.g., CA-125) aided diagnosis. Surgical excision was performed, and histopathology confirmed MBT. Postoperative follow-up included monitoring symptoms, imaging, and tumor markers. Informed consent was obtained. Results: The diagnosis of Malignant Brenner's Tumor (MBT) in the context of Residual Ovarian Syndrome (ROS) was established through imaging, histopathology, and immunohistochemistry. Surgical management was successful, with complete symptom resolution and no evidence of recurrence or metastasis during follow-up. This case underscores the significance of considering ROS as a potential site for malignant transformation. Conclusions: It's important to note that the histogenesis of malignant Brenner tumors is still an area of active research, and the exact mechanism by which these tumors develop is still not fully understood. Further research is needed to better understand the underlying biology of these tumors and to develop more effective treatments for patients with malignant Brenner tumors.